{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:09:23Z","timestamp":1648987763726},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00347-020-01085-7","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:02:43Z","timestamp":1586451763000},"page":"56-59","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ablatio retinae nach intravitrealer Ocriplasmin-Injektion"],"prefix":"10.1007","volume":"118","author":[{"given":"Michael","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kohnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"issue":"6","key":"1085_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/IAE.0000000000000519","volume":"35","author":"P Hahn","year":"2015","unstructured":"Hahn\u00a0P, Chung\u00a0MM, Flynn\u00a0HW Jr, Huang\u00a0SS, Kim\u00a0JE, Mahmoud\u00a0TH, Sadda\u00a0SR, Dugel\u00a0PU (2015) Safety profile of Ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences. Retina 35(6):1128\u20131134. https:\/\/doi.org\/10.1097\/IAE.0000000000000519","journal-title":"Retina"},{"issue":"12","key":"1085_CR2","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.ophtha.2014.07.044","volume":"121","author":"Y Itoh","year":"2014","unstructured":"Itoh\u00a0Y, Kaiser\u00a0PK, Singh\u00a0RP, Srivastava\u00a0SK, Ehlers\u00a0JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121(12):2506\u20132507.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.044 (Epub 2014 Sep 7)","journal-title":"Ophthalmology"},{"key":"1085_CR3","unstructured":"Jetrea FDA Zulassung: Phase III trials: TG-MV-006\/TG-MV-007; Zulassung Oktober 2012"},{"key":"1085_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2060765","author":"B Jonckx","year":"2017","unstructured":"Jonckx\u00a0B, Porcu\u00a0M, Candi\u00a0A, Etienne\u00a0I, Barbeaux\u00a0P, Feyen\u00a0JHM (2017) Assessment of ocriplasmin effects on the vitreoretinal compartment in porcine and human model systems. J\u00a0Ophthalmol. https:\/\/doi.org\/10.1155\/2017\/2060765 (Epub 2017 Oct 29)","journal-title":"J Ophthalmol"},{"issue":"2","key":"1085_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40123-016-0062-6","volume":"5","author":"MA Khan","year":"2016","unstructured":"Khan\u00a0MA, Haller\u00a0JA (2016) Ocriplasmin for treatment of vitreomacular traction: an update. Ophthalmol Ther 5(2):147\u2013159 (Epub 2016 Sep 12)","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"1085_CR6","doi-asserted-by":"publisher","first-page":"CD011874","DOI":"10.1002\/14651858.CD011874.pub2","volume":"17","author":"JE Neffendorf","year":"2017","unstructured":"Neffendorf\u00a0JE, Kirthi\u00a0V, Pringle\u00a0E, Jackson\u00a0TL (2017) Ocriplasmin for symptomatic vitreomacular adhesion. Cochrane Database Syst Rev 17(10):CD11874. https:\/\/doi.org\/10.1002\/14651858.CD011874.pub2 (Review. PMID: 29040800)","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1085_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3928\/23258160-20160126-09","volume":"47","author":"SP Shah","year":"2016","unstructured":"Shah\u00a0SP, Jeng-Miller\u00a0KW, Fine\u00a0HF, Wheatley\u00a0HM, Roth\u00a0DB, Prenner\u00a0JL (2016) Post-marketing survey of adverse events following ocriplasmin. Ophthalmic Surg Lasers Imaging Retina 47(2):156\u2013160","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"1085_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08820538.2016.1228416","volume":"32","author":"M Shaikh","year":"2017","unstructured":"Shaikh\u00a0M, Miller\u00a0JB, Papakostas\u00a0TD, Husian\u00a0D (2017) The efficacy and safety profile of ocriplasmin in vitreomacular interface disorders. Semin Ophthalmol 32(1):52\u201355","journal-title":"Semin Ophthalmol"},{"issue":"3","key":"1085_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/bjophthalmol-2013-304219","volume":"98","author":"RP Singh","year":"2014","unstructured":"Singh\u00a0RP, Li\u00a0A, Bedi\u00a0R, Srivastava\u00a0S, Sears\u00a0JE, Ehlers\u00a0JP, Schachat\u00a0AP, Kaiser\u00a0PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98(3):356\u2013360","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1085_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1056\/NEJMoa1110823","volume":"367","author":"P Stalmans","year":"2012","unstructured":"Stalmans\u00a0P, Benz\u00a0MS, Gandorfer\u00a0A, Kampik\u00a0A, Girach\u00a0A, Pakola\u00a0S, Haller\u00a0JA (2012) MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N\u00a0Engl J Med 367(7):606\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1110823","journal-title":"N Engl J Med"},{"issue":"4","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00417-016-3294-1","volume":"254","author":"P Stalmans","year":"2016","unstructured":"Stalmans\u00a0P (2016) A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol 254(4):617\u2013628. https:\/\/doi.org\/10.1007\/s00417-016-3294-1 (Epub 2016 Feb 22)","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1085_CR12","unstructured":"Stellungnahme von DOG, Retinologische Gesellschaft und BVA zur therapeutischen intravitrealen Anwendung von Ocriplasmin (JETREA\u00ae) in der Augenheilkunde Mai 2013; https:\/\/www.dog.org\/wp-content\/uploads\/2013\/03\/Stellungnahme_Ocriplasmin.pdf. Zugegriffen: 10. Februar 2020"},{"issue":"9","key":"1085_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jamaophthalmol.2015.1746","volume":"133","author":"R Varma","year":"2015","unstructured":"Varma\u00a0R, Haller\u00a0JA, Kaiser\u00a0PK (2015) Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol 133(9):997\u20131004. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1746","journal-title":"JAMA Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01085-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-020-01085-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01085-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:21:02Z","timestamp":1617924062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-020-01085-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s00347-020-01085-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"9 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0M\u00fcller: Vortragst\u00e4tigkeit: Alcon, Allergan, Novartis, Thea. F.\u00a0Koch: Forschungsunterst\u00fctzung: Alimera, Insight Instruments, VRmagic, Bayer. P.\u00a0Singh: Vortragst\u00e4tigkeit: Alcon, Alimera, Novartis. T.\u00a0Kohnen: Forschungsunterst\u00fctzung: Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind, Zeiss; Vortrags- und Beratungst\u00e4tigkeit: Abbott, Alcon, Geuder, J&J Vision, Oculus, Santen, Schwind, Staar, TearLab, Thea Pharma, Thieme Compliance, Ziemer, Zeiss.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}